PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

CONFIDENTIAL

FIFTH AMENDMENT TO AMENDED AND RESTATED

RESEARCH, COLLABORATION AND LICENSE AGREEMENT

This FIFTH AMENDMENT (the “Amendment”), dated April 6, 2021 (the “Fifth Amendment Effective Date”), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.

WHEREAS, the Parties entered into a Research, Collaboration & License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration & License Agreement dated May 28, 2019 (the “Collaboration Agreement”), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, the Third Amendment

dated December 23, 2020, and the Fourth Amendment also dated December 23, 2021 pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications; and

WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.Pursuant to Section 2.5.1, Licensee and Penn have agreed to initiate a Pilot Study for [***]. The Research Plan and timeline for the [***] Pilot Study is contained in the updated Exhibit B to this Fifth Amendment. The Research Program Budget for the [***] Pilot Study program is contained in the updated Exhibit C to this Fifth Amendment. The full amount of the Program Budget will be paid by Licensee within [***] days of the Fifth Amendment Effective Date.

2.If, at the conclusion of the [***] Pilot Study, Licensee elects not to move forward with an [***] Research Program, [***] shall be deleted from the definition of Exclusive DRG Indications in Section 1.105 of the Collaboration Agreement, and [***] will thereafter be considered an Exploratory DRG Technology Indication.

3.Licensee acknowledges that pursuant to Section 2.5.5, Penn has granted a license for [***] under Patent Rights Controlled by Penn and conceived and reduced to practice by the Wilson Lab to an entity controlled by [***] and Penn is not able to collaborate with Licensee on [***], and the [***] is deleted from the definition of Exploratory Indications.

4.This Fifth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Fifth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this Fifth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.

5.All terms and conditions of the Collaboration Agreement not changed by this Fifth Amendment shall remain in full force and effect.

6.Signatures on this Fifth Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.

[Remainder of the page intentionally left blank; signature page follows.]

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

AMICUS    THERAPEUTICS, INC.

By: /s/John S. Swartley    By: /s/Jeff Castelli

Name: John S. Swartley, PhD    Name: Jeff Castelli, PhD

Title: Associate Vice Provost for Research and Managing Director, Penn Center for Innovation

Read and Acknowledged:

By:     /s/ James Wilson

Name:    Dr. James M. Wilson

Title:    Director, Gene Therapy Program

Title: Chief Development Officer

Exhibit B

Pilot Study and Timeline

[***]

Exhibit C Budget

[***]